Literature DB >> 708147

Pharmacokinetics of ethosuximide in the dog.

M A el Sayed, W Löscher, H H Frey.   

Abstract

The pharmacokinetics of ethosuximide were studied in dogs and compared with the data known for man. After intravenous injection of 40 mg/kg to 9 dogs, the concentration-time curve in serum could be described by the open one-compartment model. Serum half-lives were between 11 and 25 hr, the volume of distribution correspond to between 44 and 66% of body weight. After oral administration of the same dose, maximal serum concentrations were reached within 1-4 hr and the absorption amounted to 88-95%. By treatment with three daily doses, a plateau in serum concentrations could be reached and maintained. At serum concentrations above 100 microliter/ml, half-lives seemed prolonged when compared to the values determined previously with a dose of 40 mg/kg. Ethosuximide rapidly enters the cerebrospinal fluid, equilibrium was established after 20-30 min. Plasma protein binding of the drug was negligible. Comparison of the pharmacokinetic data for dog and man reveals, in spite of the somewhat shorter half-life in the dog, a rather good agreement. In female rats, ethosuximide had an average half-life of 10 hr, in mice of hardly 1 hr. Concentrations in serum and brain of mice equilibrated within 10 min.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708147

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  6 in total

1.  Ethosuximide Reduces Mortality and Seizure Severity in Response to Pentylenetetrazole Treatment During Ethanol Withdrawal.

Authors:  Melissa A Riegle; Melissa L Masicampo; Hong Qu Shan; Victoria Xu; Dwayne W Godwin
Journal:  Alcohol Alcohol       Date:  2015-04-12       Impact factor: 2.826

Review 2.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

Review 3.  Mechanisms of anticonvulsant drug action. II. Drugs primarily used for absence epilepsy.

Authors:  C L Faingold; R A Browning
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

Review 4.  Dogs as a Natural Animal Model of Epilepsy.

Authors:  Wolfgang Löscher
Journal:  Front Vet Sci       Date:  2022-06-22

5.  Ethosuximide reduces electrographical and behavioral correlates of alcohol withdrawal seizure in DBA/2J mice.

Authors:  Melissa A Riegle; Melissa L Masicampo; Erin H Caulder; Dwayne W Godwin
Journal:  Alcohol       Date:  2014-05-04       Impact factor: 2.405

6.  Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer's disease mouse model.

Authors:  Haakon B Nygaard; Adam C Kaufman; Tomoko Sekine-Konno; Linda L Huh; Hilary Going; Samantha J Feldman; Mikhail A Kostylev; Stephen M Strittmatter
Journal:  Alzheimers Res Ther       Date:  2015-05-05       Impact factor: 6.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.